Maternal and newborn outcomes following paliperidone palmitate use during pregnancy and puerperal period in two women with schizophrenia
Küçük Resim Yok
Tarih
2017
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Cukurova Univ, Fac Medicine
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Use of long-acting antipsychotics in schizophrenia provides advantages in achievement of compliance to treatment and maintenance of treatment. There is limited information on use of Paliperidone Palmitate (PP) during period of pregnancy and puerperality. Here, it was reported that two cases with schizophrenia who used PP during period of pregnancy, at the term, had healthy and vaginal delivery and then continued to use PP for a while including period of puerperium. The assessment of infant development included pediatric and psychiatric examination, physical and neurobehavioral development measurements at 2, 6, 12, 18 and 24 months of age. In our cases, no specific risks for the mothers and their children can be attributed to the use of PP during monitoring period. A clear plan for a woman and her supports (partner and family as appropriate) for postpartum care is essential for ongoing monitoring and care. Although it was not reported that fetus exposed to antipsychotics had congenital malformation; it should be kept in mind that in the future these children can develop neurodevelopmental and neurobehavioral problems.
Açıklama
Anahtar Kelimeler
Schizophrenia, pregnancy, puerperality, infant, paliperidone palmitate
Kaynak
Cukurova Medical Journal
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
42
Sayı
4
